A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Yukinobu Watanabe, Masahiro Ogawa, Yu Tamura, Seiichiro Suda, Masahiro Kaneko, Mariko Kumagawa, Midori Hirayama, Naoki Matsumoto, Toshiki Yamamoto, Mitsuhiko Moriyama

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administration, the scans showed tumor growth, but after continuous administration of atezolizumab plus bevacizumab, the tumors finally reduced in size and showed a partial response. The transient growth of the tumors was considered to be pseudoprogression. Herein, we report a case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Original languageEnglish
JournalJournal of Investigative Medicine High Impact Case Reports
Volume9
DOIs
Publication statusPublished - Nov 2021

Keywords

  • Hepatocellular carcinoma
  • atezolizumab
  • bevacizumab
  • immune checkpoint inhibitor
  • pseudoprogression

Fingerprint

Dive into the research topics of 'A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab'. Together they form a unique fingerprint.

Cite this